Price T Rowe Associates Inc. MD Trims Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Price T Rowe Associates Inc. MD lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 30.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 288,512 shares of the medical research company's stock after selling 124,498 shares during the quarter. Price T Rowe Associates Inc. MD owned about 0.16% of IQVIA worth $56,697,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. lifted its position in shares of IQVIA by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company's stock worth $3,956,087,000 after purchasing an additional 105,504 shares during the last quarter. Canada Pension Plan Investment Board increased its position in IQVIA by 20.0% during the fourth quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock worth $841,461,000 after acquiring an additional 712,958 shares during the period. Geode Capital Management LLC lifted its position in shares of IQVIA by 1.9% in the 4th quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company's stock worth $818,315,000 after acquiring an additional 77,981 shares during the period. Invesco Ltd. grew its position in IQVIA by 53.4% in the fourth quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock valued at $509,012,000 after acquiring an additional 902,226 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of IQVIA by 2.5% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,438,726 shares of the medical research company's stock valued at $481,380,000 after acquiring an additional 59,426 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Price Performance

IQV traded up $2.32 during trading on Friday, reaching $153.42. 1,697,044 shares of the company traded hands, compared to its average volume of 1,436,228. The company has a market cap of $27.05 billion, a P/E ratio of 20.46, a PEG ratio of 1.99 and a beta of 1.46. IQVIA Holdings Inc. has a 12-month low of $135.97 and a 12-month high of $252.88. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The firm has a fifty day simple moving average of $168.27 and a 200 day simple moving average of $191.90.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. HSBC lowered shares of IQVIA from a "buy" rating to a "hold" rating and decreased their target price for the stock from $260.00 to $160.00 in a research report on Friday, April 25th. StockNews.com downgraded IQVIA from a "buy" rating to a "hold" rating in a research note on Wednesday, March 12th. Barclays reaffirmed an "equal weight" rating and set a $170.00 target price (down previously from $235.00) on shares of IQVIA in a research report on Thursday, April 10th. Truist Financial reduced their price objective on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a research report on Thursday, April 10th. Finally, UBS Group decreased their price target on IQVIA from $260.00 to $255.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Eight research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, IQVIA presently has an average rating of "Moderate Buy" and a consensus target price of $237.62.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.